Feb. 15 , 2008 - PLC Systems Inc. (Amex: PLC) announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food & Drug Administration (FDA) for its RenalGuard Therapy™ and RenalGuard System™. This supplement seeks approval to move to a pivotal trial to study the effectiveness of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy. According to the current timetable, PLC expects to commence the pivotal trial after receipt of FDA approval. Contrast-Induced Nephropathy, or CIN, is a major and growing problem due to the increasing number of older patients, diabetics and patients with pre-existing renal impairment -- all of whose conditions make them at risk for CIN when they require interventional procedures that use radiographic contrast media... PLC Systems' Press Release -
Showing posts with label PLC Systems. Show all posts
Showing posts with label PLC Systems. Show all posts
Wednesday, March 5, 2008
PLC Systems' RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy
Feb. 15 , 2008 - PLC Systems Inc. (Amex: PLC) announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food & Drug Administration (FDA) for its RenalGuard Therapy™ and RenalGuard System™. This supplement seeks approval to move to a pivotal trial to study the effectiveness of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy. According to the current timetable, PLC expects to commence the pivotal trial after receipt of FDA approval. Contrast-Induced Nephropathy, or CIN, is a major and growing problem due to the increasing number of older patients, diabetics and patients with pre-existing renal impairment -- all of whose conditions make them at risk for CIN when they require interventional procedures that use radiographic contrast media... PLC Systems' Press Release -
Subscribe to:
Posts (Atom)